A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS).
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2015
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 30 May 2014 Planned End Date changed from 1 Oct 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned patient no changed from 225 to 150 as reported by ClinicalTrials.gov.